The Lumara Series

Launching Lumara — What Success Could Look Like Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignm...

Lessons from Elsewhere — What Other TAs Are Doing Better Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch. We break down biomarker-tiered approaches and predictive outcome modeling from oncology; responder-based, modular reimbursement and pharmacy-channel starter kits from migraine; and conc...

The Unknown Unknowns — How Much Intel Are Your Competitors Gathering? Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening...

Episode 5: Scaling the Access Wall — Real-World Evidence as a Differentiator In episode 5, we explore how real-world evidence (RWE) has become the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations. We compare how leading severe-asthma brands depl...

Purpose of Episode: In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible pa...

Patient Support Showdown — HUBs, Copays, and Frictionless Starts Episode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight whe...

The Coverage Chessboard — Formulary Status and Rebate Wars Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers. We unpack the payer dynamics shaping severe asthma today—tiering norms, step edits, and prior auth criteria—then walk through what wins preferred placement: net price after rebates, label breadth an...

Meet Lumara: A New Contender in Severe Asthma In Episode 1, we introduce Lumara —a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market. With launch roughly 12 months out , early conversations with payers and providers have begun, and the competitive set— Dupixent, Fasenra, Tezspire, Nucala —is well established. We frame the stakes, su...

A Genflare-produced Podcast Series.  Series Title: The Lumara Series: A Competitive Intelligence Podcast for Market Access and Brand Leaders in Specialty Pharma Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially available GenAI tooling and systems to both generate all of the underlying content and sciences as wel...